Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Compared to Durvalumab Plus Chemotherapy in First-Line Treatment in Patients with Advanced Biliary Tract Cancer in the HarMONi-GI1 Study Conducted by Akeso in China - Companan.

Financial Times Markets · Source